Optic Neuritis

  • Jane W. Chan


Although neurologists usually diagnose and treat multiple sclerosis, the visual loss that often accompanies this disease often presents to an ophthalmologist or neuro-ophthalmologist for evaluation. It is an inflammation of one or both optic nerves resulting in (usually) temporary visual loss. It affects young to middle-aged adults between 16 and 55 years of age. The female-tomale ratio is 2:1. Children often are affected bilaterally, whereas adults are affected unilaterally. The annual incidence of acute optic neuritis has been estimated in population-based studies to be between 1 and 5 per 100,000.1,2 Clinically definite multiple sclerosis (CDMS) is apparent at the onset of optic neuritis in 15% to 20% of patients with optic neuritis; another 40% will later experience a multiple sclerosis attack.3 The clinical diagnosis and advances of understanding the pathogenesis and current recommended treatment of this disorder are outlined here.


Multiple Sclerosis Optic Nerve Optic Neuritis Optic Neuropathy Visual Evoke Potential 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kinnunen E. The incidence of optic neuritis and its prognosis for multiple sclerosis. Acta Neurol Scand 1983;68:371–377.PubMedGoogle Scholar
  2. 2.
    Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LJ. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995;45:244–250.PubMedGoogle Scholar
  3. 3.
    Cantore WA. Optic neuritis. Pa Med 1996; 99(suppl):96–98.PubMedGoogle Scholar
  4. 4.
    Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991;109:1673–1678.Google Scholar
  5. 5.
    Beck RW Optic neuritis. In: Miller NR, Newman NJ, editors. The essentials: Walsh & Hoyt’s clinical neuro-ophthalmology. Baltimore: Williams & Wilkins; 1999.Google Scholar
  6. 6.
    Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1993;111:231–234.PubMedGoogle Scholar
  7. 7.
    Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol 1994;112:946–953.PubMedGoogle Scholar
  8. 8.
    Menage MJ, Papakostopoulos D, Dean Hart JC, Papakostopoulos S, Gogolitsyn Y. The Farnsworth-Munsell 100-hue test in the first episode of demyelinating optic neuritis. Br J Ophthalmol 1993;77:68–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Engell T, Trojaborg W, Raun NE. Subclinical optic neuropathy in multiple sclerosis. A neuroophthalmological investigation by means of visually evoked response, Farnsworth-Munsell 100-hue test and Ishihara test and their diagnostic value. Acta Ophthalmol (Copenh) 1987; 65:735–740.Google Scholar
  10. 10.
    Nichols BE, Thompson HS, Stone EM. Evaluation of a significantly shorter version of the Farnsworth-Munsell 100-hue test in patients with three different optic neuropathies. J Neuro-Ophthalmol 1997;17:1–6.CrossRefGoogle Scholar
  11. 11.
    Katz B. The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc 1995;93:685–708.PubMedGoogle Scholar
  12. 12.
    Frederiksen JL, Olesen J, Larsson HB, Petrera J, Sellebjerg FT. Acute unilateral papillitis versus retrobulbar neuritis: relation to multiple sclerosis. Mult Scler 1996;l:223–227.Google Scholar
  13. 13.
    Frisen L, Hoyt WF. Insidious atrophy of retinal nerve fibers in multiple sclerosis. Funduscopic identification in patients with and without visual complaints. Arch Ophthalmol 1974;92:91–97.PubMedGoogle Scholar
  14. Spalton DJ, Hitchings RA, Hunter PA, editors; Tan JCH, associate editor; Harry J, pathology advisor. Atlas of clinical ophthalmology. Philadelphia, Edinburgh: Elsevier Mosby; 2005.Google Scholar
  15. 15.
    Lightman S, McDonald WI, Bird AC, Francis DA, Hoskins A, Batchelor JR. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987;110(pt 2):405–414.PubMedCrossRefGoogle Scholar
  16. 16.
    Killer HE, Job O. Differential diagnostic considerations on retrobulbar neuritis. Nervenarzt 1996;67:815–820.PubMedCrossRefGoogle Scholar
  17. 17.
    Swartz NG, Beck RW, Savino PJ, Sergott RC, Bosley TM, Lam BL. Pain in anterior ischemic optic neuropathy. J Neuro-Ophthalmol 1995;15: 9–10.CrossRefGoogle Scholar
  18. 18.
    Warner JE, Lesseil S, Rizzo JF III, Newman NJ. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis? Arch Ophthalmol 1997;115:1408–1410.PubMedGoogle Scholar
  19. 19.
    Smith JL, Hoyt WF, Susac JO. Ocular fundus in acute Leber optic neuropathy. Arch Ophthalmol 1973;90:349–354.PubMedGoogle Scholar
  20. 20.
    Brown MD, Torroni A, Reckord CL, et al. Phylogenetic analysis of Caucasian 11778-positive and 11778-negative Leber’s hereditary optic neuropathy patients indicates multiple independent occurrences of the common primary mitochondrial DNA mutations. Hum Mutat 1995;6(4):311–325.PubMedCrossRefGoogle Scholar
  21. 21.
    Selbst RG, Selhorst JB, Harbison JW, et al. Parainfectious optic neuritis: report and review following varicella. Arch Neurol 1983;40: 347–350.PubMedGoogle Scholar
  22. 22.
    Manor RS, Cohen S, Ben-Sira T. Bilateral acute retrobulbar optic neuropathy associated with epidemic keratoconjunctivitis in a compromised host. Arch Ophthalmol 1986;104: 1271–1272.PubMedGoogle Scholar
  23. 23.
    Spalton DJ, Murdoch I, Holder GE. Coxsackie B5 papillitis. J Neurol Neurosurg Psychiatry 1989;52:1310–1311.PubMedGoogle Scholar
  24. 24.
    McKibbin M, Cleland PG, Morgan SJ. Bilateral optic neuritis after hepatitis A. J Neurol Neurosurg Psychiatry 1995;58(4):508.PubMedGoogle Scholar
  25. 25.
    Achiron LR. Postinfectious hepatitis B optic neuritis. Optom Vis Sci 1994;71:53–56.PubMedCrossRefGoogle Scholar
  26. 26.
    Gross JG, Sadun AA, Wiley CA, et al. Severe visual loss related to isolated peripapillary retinal and optic nerve head cytomegalovirus infection. Am J Ophthalmol 1989;108:691–698.PubMedGoogle Scholar
  27. 27.
    Jones J, Gardner W, Newman T. Severe optic neuritis in infectious mononucleosis. Ann Emerg Med 1988;17:361–364.PubMedCrossRefGoogle Scholar
  28. 28.
    Sweeney BJ, Manji H, Gilson RJC, et al. Optic neuritis and HIV-1 infection. J Neurol Neurosurg Psychiatry 1993;56:705–707.PubMedGoogle Scholar
  29. 29.
    Srivastava SP, Neman HV. Optic neuritis in measles. Br J Ophthalmol 1963;47:180–181.PubMedCrossRefGoogle Scholar
  30. 30.
    Strong LE, Henderson JW, Gangitano JL. Bilateral retrobulbar neuritis secondary to mumps. Am J Ophthalmol 1974;78:331–332.PubMedGoogle Scholar
  31. 31.
    Connolly JH, Hutchinson WM, Allen IV, et al. Carotid artery thrombosis, encephalitis, myelitis and optic neuritis associated with rubella virus infections. Brain 1975;98:583–594.PubMedCrossRefGoogle Scholar
  32. 32.
    Purvin V, Hrisomalos N, Dunn D. Varicella optic neuritis. Neurology 1988;38:501–503.PubMedGoogle Scholar
  33. 33.
    Pless ML, Malik SI. Relapsing-remitting, corticosteroid-sensitive, varicella zoster virus optic neuritis. Pediatr Neurol 2003;29(5):422–424.PubMedCrossRefGoogle Scholar
  34. 34.
    Deane JS, Bibby K. Bilateral optic neuritis following herpes zoster ophthalmicus. Arch Ophthalmol 1995;113:972–973.PubMedGoogle Scholar
  35. 35.
    Colarizi A, Panico E. Atrofia secondaria del nervo ottico consecutiva a infezione carbonchiosa. Bull Acad Med Roma 1933;59:399–408.Google Scholar
  36. 36.
    Smallberg GJ, Sherman SH, Pezeshkpour GH, et al. Optic neuropathy due to brain abscess. Am J Ophthalmol 1976;82:188–192.PubMedGoogle Scholar
  37. 37.
    McLean Dr, Russell N, Khan MY. Neurobrucellosis: clinical and therapeutic features. Clin Infect Dis 1992;15:582–590.PubMedGoogle Scholar
  38. 38.
    Brazis PW, Stokes HR, Ervin FR. Optic neuritis in cat scratch disease. J Clin Neuro-Ophthalmol 1986;6:172–174.Google Scholar
  39. 39.
    Ellsworth J, Marks MI, Vose A. Meningococcal meningitis in children. Can Med Assoc J 1979; 120(2):155–158.PubMedGoogle Scholar
  40. 40.
    Miller HG, Staton JB, Gibbons JL. Parainfectious encephalomyelitis and related syndromes: a critical review of the neurological complications of certain specific fevers. Q J Med 1956;25:427–505.PubMedGoogle Scholar
  41. 41.
    Miller BW, Frenkel M. Report of a case of tuberculosis retrobulbar neuritis and osteomyelitis. Am J Ophthalmol 1971;71:751–756.PubMedGoogle Scholar
  42. 42.
    Bajpai PC, Dikshit SK. Bilateral optic neuritis and encephalitis accompanying typhoid. J Indian Med Assoc 1958;30:54–57.PubMedGoogle Scholar
  43. 43.
    Vital Durand D, Gerard A, Rousset H. Neurological manifestations of Whipple disease (in French). Rev Neurol 2002;158(10Cl):988–992.PubMedGoogle Scholar
  44. 44.
    Yen M-Y, Lui J-H. Bilateral optic neuritis following Bacille Calmette-Guerin (BCG) vaccination. J Clin Neuro-Ophthalmol 1991; 114:2437–2450.Google Scholar
  45. 45.
    Berkman N, Banzarti T, Dhaoui R, et al. Neuropapillite bilaterale avec decollement sereux du neuroepithelium, au decours d’une vaccination contre l’hepatite B. Bull Soc Ophtalmol Fr 1996;96:187–190.Google Scholar
  46. 46.
    Chayakul V, Ishikawa S, Chotibut S, et al. Convergence insufficiency and optic neuritis due to anti-rabies inoculation. Jpn J Ophthalmol 1975;19:307–314.Google Scholar
  47. 47.
    Dadeya S, Guliani BP, Gupta VS, Malik KP, Jain DC. Retrobulbar neuritis following rabies vaccination. Trop Doct 2004;34(3):174–175.PubMedGoogle Scholar
  48. 48.
    Topaloglu H, Berker M, Kansu T, et al. Optic neuritis and myelitis after booster tetanus toxoid vaccination. Lancet 1992;339:178–179.PubMedCrossRefGoogle Scholar
  49. 49.
    Wagener HP. Edema of the optic disks in cases of encephalitis. Am J Med Sci 1952;223:205–215.PubMedCrossRefGoogle Scholar
  50. 50.
    Perry HD, Mallen FJ, Grodin RW, et al. Reversible blindness in optic neuritis associated with influenza vaccination. Ann Ophthalmol 1979;11: 545–550.PubMedGoogle Scholar
  51. 51.
    Payne DC, Rose CE Jr, Kerrison J, Aranas A, Duderstadt S, McNeil MM. Anthrax vaccination and risk of optic neuritis in the United States military, 1998–2003. Arch Neurol 2006; 63(6):871–875.PubMedCrossRefGoogle Scholar
  52. 52.
    Graham EM, Ellis CJK, Sanders MD, et al. Optic neuropathy in sarcoidosis. J Neurol Neurosurg Psychiatry 1986;49:756–763.PubMedGoogle Scholar
  53. 53.
    Golnik KC, Newman SA, Wispelway B. Cryptococcal optic neuropathy in the acquired immune deficiency syndrome. J Clin Neuro-Ophthalmol 1991;11:96–103.Google Scholar
  54. 54.
    Gross JG, Sadun AA, Wiley CA, et al. Severe visual loss related to isolated peripapillary retinal and optic nerve head cytomegalovirus infection. Am J Ophthalmol 1989;108:691–698.PubMedGoogle Scholar
  55. 55.
    Grossniklaus HE, Frank KE, Tomsak RL. Cytomegalovirus retinitis and optic neuritis in acquired immune deficiency syndrome: report of a case. Ophthalmology 1987;94:1601–1604.PubMedGoogle Scholar
  56. 56.
    Litoff D, Catalano RA. Herpes zoster optic neuritis in human immunodeficiency virus infection. Arch Ophthalmol 1990;108:782–783.PubMedGoogle Scholar
  57. 57.
    Zambrano W, Perez GM, Smith JL. Acute syphilitic blindness in AIDS. J Clin Neuro-Ophthalmol 1987;7:1–5.CrossRefGoogle Scholar
  58. 58.
    Nichols JW, Goodwin JA. Neuro-ophthalmologic complications of AIDS. Semin Ophthalmol 1992;7:24–29.CrossRefGoogle Scholar
  59. 59.
    Falcone PM, Notis C, Merhige K. Toxoplasmic papillitis as the initial manifestation of acquired immunodeficiency syndrome. Ann Ophthalmol 1993;25:56–57.PubMedGoogle Scholar
  60. 60.
    Baglivo E, Safran AB, Borruat FX. Multiple evanescent white dot syndrome after hepatitis B vaccine. Am J Ophthalmol 1996;122(3): 431–432.PubMedGoogle Scholar
  61. 61.
    Lee MS, Cooney EL, Stoessel KM, Gariano RF. Varicella zoster virus retrobulbar optic neuritis preceding retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1998;105(3):467–471.PubMedCrossRefGoogle Scholar
  62. 62.
    Bert RJ, Samawareerwa R, Melhem ER. CNS MR and CT findings associated with a clinical presentation of herpetic acute retinal necrosis and herpetic retrobulbar optic neuritis: five HIV-infected and one non-infected patients. AJNR Am J Neuroradiol 2004;25(10):1722–1729.PubMedGoogle Scholar
  63. 63.
    Winward KE, Hamed LM, Glaser JS. The spectrum of optic nerve disease in human immunodeficiency virus infection. Am J Ophthalmol 1989;107(4):373–380.PubMedGoogle Scholar
  64. 64.
    Bakri SJ, Kaiser PK. Ocular manifestations of West Nile virus. Curr Opin Ophthalmol 2004; 15(6):537–540.PubMedCrossRefGoogle Scholar
  65. 65.
    Holland GN, Engstrom RE Jr, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1988;106:653–657.PubMedGoogle Scholar
  66. 66.
    Larsen M, Toft PB, Bernhard P, Herning M. Bilateral optic neuritis in acute human immunodeficiency virus infection. Acta Ophthalmol Scand 1998;76(6):737–738.PubMedCrossRefGoogle Scholar
  67. 67.
    Newman NJ, Lesseil S. Bilateral optic neuropathies with remission in two HIV-positive men. J Clin Neuro-Ophthalmol 1992;12(1): 1–5.Google Scholar
  68. 68.
    Jacobson DM, Marx JJ, Dlesk A. Frequency and clinical significance of Lyme seropositivity in patients with isolated optic neuritis. Neurology 1991;41:706–711.PubMedGoogle Scholar
  69. 69.
    Sanborn GE, Kivlin JD, Stevens M. Optic neuritis secondary to sinus disease. Arch Otolaryngol 1984;110(12):816–819.PubMedGoogle Scholar
  70. 70.
    Gass JDM. Diseases of the optic nerve that may simulate macular disease. Trans Am Acad Ophthalmol Otolaryngol 1977;83:766–769.Google Scholar
  71. 71.
    Moreno RJ, Weisman J, Waller S. Neuroretinitis: an unusual presentation of ocular toxoplasmosis. Ann Ophthalmol 1992;24:68–70.PubMedGoogle Scholar
  72. 72.
    Farthing CF, Howard RS, Thin RN. Papillitis and hepatitis B. Br Med J 1986;29(2):1712.Google Scholar
  73. 73.
    Knapp A. Optic neuritis after influenza, with changes in the spinal fluid. Arch Ophthalmol 1916;45:247–249.Google Scholar
  74. 74.
    Arruga J, Valentines J, Mauri F, et al. Neuroretinitis in acquired syphilis. Ophthalmology 1985;92:262–270.PubMedGoogle Scholar
  75. 75.
    Audry-Chaboud D, Durnas R, Audry F, et al. Coxsackie B virus neuropapillitis. Rev Otoneuro-Ophthalmol 1981;53:473–482.Google Scholar
  76. 76.
    Folk JC, Weingeist TA, Corbett JJ, et al. Syphylitic neuroretinitis. Am J Ophthalmol 1983;95:480.PubMedGoogle Scholar
  77. 77.
    Copeland RA Jr. Lyme uveitis. Int Ophthalmol Clin 1990;30:291.PubMedGoogle Scholar
  78. 78.
    Barkay S, Garzozi H. Leptospirosis and uveitis. Ann Ophthalmol 1984;16:164.PubMedGoogle Scholar
  79. 79.
    Tabbara KF. Brucellosis and nonsyphilitic treponemal uveitis. Int Ophthalmol Clin 1990; 30:294.PubMedGoogle Scholar
  80. 80.
    Jampol LM, Staruch S, Albert DM. Intraocular nocardiosis. Am J Ophthalmol 1973;76:568.PubMedGoogle Scholar
  81. 81.
    Schlaegel TF, O’Connor GR. Tuberculosis and syphilis. Arch Ophthalmol 1981;99:2206.PubMedGoogle Scholar
  82. 82.
    Jay WM, Schanzlin DJ, Fritz KJ. Medical therapy of metastatic meningococcal endophthalmitis. Am J Ophthalmol 1979;87:567.PubMedGoogle Scholar
  83. 83.
    Murray HW, Knox DL, Green WR, et al. Cytomegalovirus retinitis in adults: a manifestation of disseminated viral infection. Am J Med 1977;63:574.PubMedCrossRefGoogle Scholar
  84. 84.
    Pavan-Langston D, Brockhurst RJ. Herpes simplex panuveitis. Arch Ophthalmol 1969; 81:783.PubMedGoogle Scholar
  85. 85.
    Brown RM, Mendis U. Retinal arteritis complicating herpes zoster ophthalmicus. Br J Ophthalmol 1973;57:344.PubMedCrossRefGoogle Scholar
  86. 86.
    Krill AE. The retinal disease of rubella. Arch Ophthalmol 1967;77:445.PubMedGoogle Scholar
  87. 87.
    Arshi S, Sadeghi-Bazargani H, Ojaghi H, et al. The first rapid onset optic neuritis after measlesrubella vaccination: case report. Vaccine 2004; 22(25–26):3240–3242.PubMedCrossRefGoogle Scholar
  88. 88.
    Font RL, Jenis EH, Tuck KD. Measles maculopathy associated with subacute sclerosing panencephalitis (SSPE). Arch Pathol 1973;96: 168.PubMedGoogle Scholar
  89. 89.
    Shuman JS, Orellana J, Friedman AH, et al. Acquired immunodeficiency syndrome (AIDS). Surv Ophthalmol 1987;31:384.CrossRefGoogle Scholar
  90. 90.
    Gagliuso DJ, Teich SA, Friedman AH, et al. Ocular toxoplasmosis in AIDS patients. Trans Am Ophthalmol Soc 1990;88:63.PubMedGoogle Scholar
  91. 91.
    Wilkinson CP. Ocular toxocariasis. In: Schachat AP, Murphy RB, Patz A, editors. Retina, vol. 2. St. Louis: Mosby; 1989.Google Scholar
  92. 92.
    Bird AC, Anderson J, Fuglsang H. Morphology of posterior segment lesions of the eye in patients with onchocerciasis. Br J Ophthalmol 1976;60:2.PubMedCrossRefGoogle Scholar
  93. 93.
    Tabbara KF. Endogenous ocular candidiasis. In: Tabbara KF, Hyndiuk RA, editors. Infections of the eye. Boston: Little, Brown; 1986.Google Scholar
  94. 94.
    Schlaegel TF. Presumed ocular histoplasmosis. In: Tasman W, Jaeger EA, editors: Duane’s clinical ophthalmology, vol. 4. Philadelphia: Lippincott; 1981.Google Scholar
  95. 95.
    Shields JA, Wright DM, Augsberger JJ, et al. Cryptococcal chorioretinitis. Am J Ophthalmol 1980;89:210.PubMedGoogle Scholar
  96. 96.
    Naidoff MA, Green WR. Endogenous Aspergillus endophthalmitis occurring after kidney transplant. Am J Ophthalmol 1975;79:502.PubMedGoogle Scholar
  97. 97.
    Zakka KA, Foos RY, Brown WJ. Intraocular coccidioidomycosis. Surv Ophthalmol 1978;22: 313.PubMedCrossRefGoogle Scholar
  98. 98.
    Bond WI, Sanders CV, Joffe L, et al. Presumed blastomycosis endophthalmitis. Ann Ophthalmol 1982;14:1183.PubMedGoogle Scholar
  99. 99.
    Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA. Ocular complications of Wegener’s granulomatosis. Ophthalmology 1983;90:279–290.PubMedGoogle Scholar
  100. 100.
    Haynes BF, Fishman ML, Fauci AS, Wolff SM. The ocular manifestations of Wegener’s granulomatosis. Fifteen years experience and review of the literature. Am J Med 1977;63:131.PubMedCrossRefGoogle Scholar
  101. 101.
    Baer JC, Raizman MB, Foster CS. Ocular Behcet’s disease in the U.S.: clinical presentation and visual outcome in 29 patients. In: Masahiko U, Shigeaki O, Koki A, editors. Proceedings of the 5th international symposium on the immunology and immunopathology of the eye, Tokyo, 13–15 March, 1990. New York: Elsevier; 1990.Google Scholar
  102. 102.
    Oppenheimer S, Hoffbrand BI. Optic neuritis and myelopathy in SLE. Can J Neurol Sci 1986;13:129.PubMedGoogle Scholar
  103. 103.
    Svitra PP, Perry H. Vogt-Koyanagi-Harada (uveomeningitic) syndrome. In: Albert DM, Jakobiec FA, editors. Principles and practice of ophthalmology. Philadelphia: Sanders; 1994.Google Scholar
  104. 104.
    Kincaid MC, Green WR. Ocular and orbital involvement in leukaemia. Surv Ophthalmol 1983;27:211–232.PubMedCrossRefGoogle Scholar
  105. 105.
    Qualman SJ, Mendelsohn G, Mann RB, Green WR. Intraocular lymphomas: Natural history based on a clinicopathologic study of eight cases and review of the literature. Cancer (Phila) 1983;52:878–886.CrossRefGoogle Scholar
  106. 106.
    Font RL, Naumann G, Zimmerman LE. Primary malignant melanoma of the skin metastatic to the eye and orbit. Am J Ophthalmol 1967;63:738–754.PubMedGoogle Scholar
  107. 107.
    Stephens RF, Shields JA. Diagnosis and management of cancer metastatic to the uvea: a study of 70 cases. Ophthalmology 1979;86:1336–1349.PubMedGoogle Scholar
  108. 108.
    Ryan SJ, Maumenee AE. Birdshot retinochoroidopathy. Am J Ophthalmol 1980;89:31.PubMedGoogle Scholar
  109. 109.
    Kirkham TH, Ffytche TJ, Sanders MD. Placoid pigment epitheliopathy with retinal vasculitis and papillitis. Br J Ophthalmol 1972;56:875.PubMedCrossRefGoogle Scholar
  110. 110.
    Dodwell DG, Jampol LM, Rosenburg M, et al. Optic nerve involvement associated with MEWDS. Ophthalmology 1990;97:862.PubMedGoogle Scholar
  111. 111.
    Fujisawa C, Fujiara H, Hasegawa E, et al. The cases of serpiginous choroiditis (in Japanese). Nippon Ganka Gakkai Zasshi 1978;82:135.PubMedGoogle Scholar
  112. 112.
    McCluskey PJ, Watson PG, Lightman S, Haybittle J, Restori M, Branley M. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 1999;106:2380–2386.PubMedCrossRefGoogle Scholar
  113. 113.
    Dutton D, Burde RM, Klingele TG. Autoimmune retrobulbar optic neuritis. Am J Ophthalmol 1982;94:11–17.PubMedGoogle Scholar
  114. 114.
    I’Jdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? [see comments]. Lupus 1999;8:109–115.CrossRefGoogle Scholar
  115. 115.
    Sakuma R, Fujihara K, Sato N, Mochizuki H, Itoyama Y. Optic-spinal form of multiple sclerosis and anti-thyroid autoantibodies. J Neurol 1999;246:449–453.PubMedCrossRefGoogle Scholar
  116. 116.
    Bennet WM. Bronchial carcinoma presenting with non-metastatic bilateral papillitis. Br Dis Chest 1986;80:189–190.CrossRefGoogle Scholar
  117. 117.
    Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol 1988;45:353–356.Google Scholar
  118. 118.
    Coppeto JR, Monteiro ML, Cannarozzi DB. Optic neuropathy associated with chronic lymphomatous meningitis. J Clin NeuroOphthalmol 1988;8:39–45.PubMedGoogle Scholar
  119. 119.
    Pillay N, Gilbert D, Ebers GC, Brown JD. Internuclear ophthalmoplegia and “optic neuritis”: paraneoplastic effects of bronchial carcinoma. Neurology 1984;34:788–791.PubMedGoogle Scholar
  120. 120.
    Perkin GD, Rose FC. Optic neuritis and its differential diagnosis. New York: Oxford University Press; 1979.Google Scholar
  121. 121.
    Engell T, Sellebjerg E, Jensen C. Changes in the retinal veins in acute optic neuritis. Acta Neurol Scand 1999;100:81–83.PubMedGoogle Scholar
  122. 122.
    Traugott U, Raine CS, McFarlin DE. Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol 1985;91:240–254.PubMedCrossRefGoogle Scholar
  123. 123.
    Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993;33:137–151.PubMedCrossRefGoogle Scholar
  124. 124.
    Frick E. Optic neuritis and multiple sclerosis. Cell-mediated cytotoxicity by peripheral blood lymphocytes against basic protein of myelin, encephalitogenic peptide, cerebrosides and gangliosides. Eur Neurol 1988;28:120–125.PubMedCrossRefGoogle Scholar
  125. 125.
    Sellebjerg E, Christiansen M, Nielsen PM, Frederiksen JL. Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis. Mult Scler 1998;4:475–479.PubMedGoogle Scholar
  126. 126.
    Soderstrom M, Link H, Xu Z, Frederiksson S. Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. Neurology 1993;43: 1215–1222.PubMedGoogle Scholar
  127. 127.
    Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;45:322–333.PubMedCrossRefGoogle Scholar
  128. 128.
    Shields DC, Tyor WR, Deibler GE, Banik NL. Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. Brain Res 1998;784:299–304.PubMedCrossRefGoogle Scholar
  129. 129.
    Inuzuka T, Sato S, Baba H, Miyatake T. Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases. Acta Neurol Scand 1987;76:18–23.PubMedGoogle Scholar
  130. 130.
    Navikas V, He B, Link J, Haglund M, Soderstrom M, Frederikson S. Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain 1996;119(pt l):213–223.PubMedCrossRefGoogle Scholar
  131. 131.
    Potter NT, Bigazzi PE. Acute optic neuritis associated with immunization with the CNS myelin proteolipid protein. Invest Ophthalmol Vis Sci 1992;33:1717–1722.PubMedGoogle Scholar
  132. 132.
    Sellebjerg FT, Frederiksen JL, Olsson T. Antimyelin basic protein and anti-proteolipid protein antibody-secreting cells in the cerebrospinal fluid of patients with acute optic neuritis. Arch Neurol 1994;51:1032–1036.PubMedGoogle Scholar
  133. 133.
    Warren KG, Catz I, Johnson E, Mielke B. Antimyelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1994;35:280–289.PubMedCrossRefGoogle Scholar
  134. 134.
    Sellebjerg F, Madsen HO, Frederiksen JL, Ryder LP, Svejgaard A. Acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system. Ann Neurol 1995;38:943–950.PubMedCrossRefGoogle Scholar
  135. 135.
    Sadovnik AD, Baird PA, Ward RH. Multiple sclerosis: updated risks for relatives. Am J Med Genet 1988;29:533–541.CrossRefGoogle Scholar
  136. 136.
    Wilkstrom J, Kinnunen E, Porras J. The agespecific prevalence ratio of familial multiple sclerosis. Neuroepidemiology 1984;3:74–82.CrossRefGoogle Scholar
  137. 137.
    Ebers GC, Bulman DE, Sadovnick AD, et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986;315:1638–1642.PubMedGoogle Scholar
  138. 138.
    Kinnunen E, Koskenvuo M, Kaprio J, Aho K. Multiple sclerosis in a nation-wide series of twins. Neurology 1987;37:1627–1629.PubMedGoogle Scholar
  139. 139.
    Sadovnik AD, Armstrong H, Rice GPA, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993;33:281–285.CrossRefGoogle Scholar
  140. 140.
    Mumford CJ, Wood NW, Kellar-Wood H, et al. The UK study of multiple sclerosis in twins. J Neurol 1992;239(suppl 2):62 (abstract).Google Scholar
  141. 141.
    Doolittle TH, Myers RH, Lehrich JR, et al. Multiple sclerosis sibling pairs: clustered onset and familial predisposition. Neurology 1990;40: 1546–1552.PubMedGoogle Scholar
  142. 142.
    Bulman DE, Sadovnik AD, Ebers GC. Age of onset in siblings concordant for multiple sclerosis. Brain 1991;114:937–950.PubMedCrossRefGoogle Scholar
  143. 143.
    Haines JL, Terwedow HA, Burgess K, et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet 1998;7(8):1229–1234.PubMedCrossRefGoogle Scholar
  144. 144.
    The Multiple Sclerosis Group, Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002;125:150–158.PubMedCrossRefGoogle Scholar
  145. 145.
    Butterfield RJ, Blankenhorn EP, Roper RJ, Zachary JF, Doerge RW, Teuscher C. Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. Am J Pathol 2000;157:637–645.PubMedGoogle Scholar
  146. 146.
    Sobel RA. Genetic and epigenetic influence on EAE phenotypes induced with different encephalitogenic peptides. J Neuroimmunol 2000;108:45–52.PubMedCrossRefGoogle Scholar
  147. 147.
    Pericak-Vance MA, Rimmler JB, Martin ER, et al. Linkage and association analysis of chromosome 19ql3 in multiple sclerosis. Neurogenetics 2001;3(4):195–201.PubMedCrossRefGoogle Scholar
  148. 148.
    Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL. Multiple sclerosis. Genomicrewards. [Review] J Neuroimmunol 2001;113:171–184.PubMedCrossRefGoogle Scholar
  149. 149.
    Kaiman B, Rodriguez-Valdez JL, Bosch U, Lublin PD. Screening for Leber’s hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis. Mult Scler 1997;2:279–282.Google Scholar
  150. 150.
    Kheradvar A, Tabassi AR, Nikbin B, et al. Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study. Mult Scler 2004;10(5):526–531.PubMedCrossRefGoogle Scholar
  151. 151.
    Rizzo JF, Lesseil S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-termprospective study. Neurology 1988;38: 185–190.PubMedGoogle Scholar
  152. 152.
    Beck RW, Arrington J, Murragh FR, Cleary PA, Kaufman DI. Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group. Arch Neurol 1993;50: 841–846.PubMedGoogle Scholar
  153. 153.
    Beck RW, Trobe JD. The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group. J NeuroOphthalmol 1995;15:131–135.PubMedGoogle Scholar
  154. 154.
    Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979;29(9 pt l):1228–1235.PubMedGoogle Scholar
  155. 155.
    Sandberg-Wollheim M, Brynke H, Cronqvist S, Holtas S, Platz P, Ryder LP. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 1990;27:386–393.PubMedCrossRefGoogle Scholar
  156. 156.
    Druschky A, Heckmann JG, Claus D, Katalinic A, Druschky KF, Neundorfer B. Progression of optic neuritis to multiple sclerosis: an 8-year follow-up study. Clin Neurol Neurosurg 1999; 101:189–192.PubMedCrossRefGoogle Scholar
  157. 157.
    Beck RW, Trobe JD, Moke PS, et al.; Optic Neuritis Study Group. Highand low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003;121(7):944–949.PubMedCrossRefGoogle Scholar
  158. 158.
    Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346(3): 199–200.CrossRefGoogle Scholar
  159. 159.
    Miller DH, Ormerod IE, McDonald WI, MacManus DG, Kendall BE, Kingsley DP. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry 1988;51:1569–1571.PubMedGoogle Scholar
  160. 160.
    Guy J, Fitzsimmons J, Ellis EA, Beck B, Mancuso A. Intraorbital optic nerve and experimental optic neuritis. Correlation of fat suppression magnetic resonance imaging and electron microscopy. Ophthalmology 1992;99:720–725.PubMedGoogle Scholar
  161. 161.
    Guy J, Mao J, Bidgood WD Jr, Mancuso A, Quisling RG. Enhancement and demyelination of the intraorbital optic nerve. Fat suppression magnetic resonance imaging. Ophthalmology 1992;99:713–719.PubMedGoogle Scholar
  162. 162.
    Cornblath WT, Quint DJ. MRI of optic nerve enlargement in optic neuritis. Neurology 1997; 48:821–825.PubMedGoogle Scholar
  163. 163.
    Rolak LA, Beck RW, Paty DW, Tourtellotte WW, Whitaker JN, Rudick RA. Cerebrospinal fluid in acute optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology 1996; 46:368–372.PubMedGoogle Scholar
  164. 164.
    Ghezzi A, Torri V, Zaffaroni M. Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI. Ital J Neurol Sci 1996;17:325–332.PubMedCrossRefGoogle Scholar
  165. 165.
    Andersson T, Siden A. An analysis of VEP components in optic neuritis. Electromyogr Clin Neurophysiol 1995;35:77–85.PubMedGoogle Scholar
  166. 166.
    Spehlmann R. Evoked potential primer, 1st ed. Boston: Butterworth; 1985.Google Scholar
  167. 167.
    Fraser C, Klistorner A, Graham S, Garrick R, Billson F, Grigg J. Multifocal visual evoked potential latency analysis: predicting progression to multiple sclerosis. Arch Neurol 2006;63(6):847–850.PubMedCrossRefGoogle Scholar
  168. 168.
    Sergott RC. Optical coherence tomography: measuring in vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis. Curr Opin Ophthalmol 2005;16(6):346–350.PubMedCrossRefGoogle Scholar
  169. 169.
    Sorensen TL, Frederikson JL, Bronnum-Hansen H, Petersen HC. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology 1999;53:473–478.PubMedGoogle Scholar
  170. 170.
    Cole SR, Beck RW, Moke PS, Kaufinail DI, Tourtellotte WW. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998;51:885–887.PubMedGoogle Scholar
  171. 171.
    Beck RW, Cleary FA. Optic neuritis treatment trial. One-year follow-up results [see comments]. Arch Ophthalmol 1993;111:773–775.PubMedGoogle Scholar
  172. 172.
    Fleishman JA, Beck RW, Linares DA, Klein JW. Deficits in visual function after resolution of optic neuritis. Ophthalmology 1987;94:1029–1035.PubMedGoogle Scholar
  173. 173.
    Franklin CR, Brickner RM. Vasospasm associated with multiple sclerosis. Arch Neurol Psychiatry 1947;58:125–162.Google Scholar
  174. 174.
    Goldstein JE, Cogan DG. Exercise and the optic neuropathy of multiple sclerosis. Arch Ophthalmol 1964;72:168–170.PubMedGoogle Scholar
  175. 175.
    Uhthoff W. Untersuchungen uber die bei der multiplen herdsklerose vorkommenden augenstorungen. Arch Psychiatr Nervenkr 1890;21; 55–116,303–410.CrossRefGoogle Scholar
  176. 176.
    Scholl GB, Song H-S, Wray SH. Uhthoffs symptom in optic neuritis: relationship to magnetic resonance imaging and development of multiple sclerosis. Ann Neurol 1991;30:180–184.PubMedCrossRefGoogle Scholar
  177. 177.
    Smith JL, Hoyt WF, Susac JO. Ocular fundus in acute Leber optic neuropathy. Arch Ophthalmol 1973;90:349–354.PubMedGoogle Scholar
  178. 178.
    Nelson D, Jeffreys WH, McDowell F. Effect of induced hyperthermia on some neurological diseases. Arch Neurol Psychiatry 1958;79: 31–39.Google Scholar
  179. 179.
    Persson HE, Sachs E. Visual evoked potentials elicited by pattern reversal during provoked visual impairment in multiple sclerosis. Brain 1981;104:369–382.PubMedCrossRefGoogle Scholar
  180. 180.
    Dunker S, Wiegand W. Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis. Ophthalmology 1996;103: 1768–1773.PubMedGoogle Scholar
  181. 181.
    Cleary FA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuro-Ophthalmol 1997;17:18–23; quiz 24-8.CrossRefGoogle Scholar
  182. 182.
    Kupersmith MJ, Nelson JI, Seiple WH, Carr RE. Electrophysiological confirmation of orientation-specific contrast losses in multiple sclerosis. Ann NY Acad Sci 1984;436:487–491.PubMedCrossRefGoogle Scholar
  183. 183.
    Halliday AM, McDonald WI, Mushin J. Delayed visual evoked response in optic neuritis. Lancet 1972;l:982–985.CrossRefGoogle Scholar
  184. 184.
    Frederiksen JL, Petrera J, Larsson HB, Stigsby B, Olesen J. Serial MRI, VEP, SEP and biotesiometry in acute optic neuritis: value of baseline results to predict the development of new lesions at one year follow up. Acta Neurol Scand 1996;93:246–252.PubMedCrossRefGoogle Scholar
  185. 185.
    Kurland LT, Beebe GW, Kurtzke JF, Nagler B, Auth TL, Lessen S. Studies on the natural history of multiple sclerosis. 2. The progression of optic neuritis to multiple sclerosis. Acta Neurol Scand 1966;42(suppl):157–176.PubMedGoogle Scholar
  186. 186.
    Pirko I, Blauwet LK, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol 2004;61(9):1401–1405.PubMedCrossRefGoogle Scholar
  187. 187.
    Morrissey SP, Bormat FX, Miller DH, Moseley IF, Sweeney MG, Govan GG. Bilateral simultaneous optic neuropathy in adults: clinical, imaging, serological, and genetic studies. J Neurol Neurosurg Psychiatry 1995;58:70–74.PubMedGoogle Scholar
  188. 188.
    Hutchinson WM. Acute optic neuritis and the prognosis for multiple sclerosis. J Neurol Neurosurg Psychiatry 1976;39:283–289.PubMedGoogle Scholar
  189. 189.
    Keast-Butler J, Taylor D. Optic neuropathies in children. Trans Ophthalmol Soc U K 1980; 100(pt l):111–118.PubMedGoogle Scholar
  190. 190.
    Tekavcic-Pompe M, Stirn-Kranjc B, Brecelj J. Optic neuritis in children: clinical and electrophysiological follow-up. Doc Ophthalmol 2003; 107(3):261–270.PubMedCrossRefGoogle Scholar
  191. 191.
    Haller P, Patzgold U. Die Optikusneuritis im Kindesalter. Fortschr Neurol Psychiatr 1979;47: 209–216.Google Scholar
  192. 192.
    Kriss A, Francis DA, Cuendet F, et al. Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry 1988;51:1253.PubMedGoogle Scholar
  193. 193.
    Riikonen R. The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children. Acta Neurol (Scand) 1989; 80:425–431.Google Scholar
  194. 194.
    Kennedy C, Carter S. Relation of optic neuritis to multiple sclerosis in children. Paediatrics 1961;28:377–387.Google Scholar
  195. 195.
    Kennedy C, Carroll FD. Optic neuritis in children. Arch Ophthalmol 1960;63:747–755.PubMedGoogle Scholar
  196. 196.
    Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children. J Pediatr Ophthalmol Strabismus 2000;37(5):254–259.PubMedGoogle Scholar
  197. 197.
    Beck RW, Cleary FA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994;101:1771–1778.PubMedGoogle Scholar
  198. 198.
    Beck RW, Cleary PA, Trobe JD, Kaufman DR, Kupersmith D, Paty DW. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group [see comments]. N Engl J Med 1993;329:1764–1769.PubMedCrossRefGoogle Scholar
  199. 199.
    Beck RW. The optic neuritis treatment trial. Implications for clinical practice. Optic Neuritis Study Group [editorial]. Arch Ophthalmol 1992;110:331–332.PubMedGoogle Scholar
  200. 200.
    Chrousos GA, Katrah JC, Beck RW, Cleary FA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993;269:2110–2112.PubMedCrossRefGoogle Scholar
  201. 201.
    Cleary FA, Beck RW, Anerson MM Jr, Kenny DJ, Backlund JY, Gilbert FR. Design, methods, and conduct of the Optic Neuritis Treatment Trial. Control Clin Trials 1993;14:123–142.PubMedCrossRefGoogle Scholar
  202. 202.
    Dalakas MC. Intravenous immune globulin therapy for neurologic diseases [see comments]. Ann Intern Med 1997;126: 721–730.PubMedGoogle Scholar
  203. 203.
    Schuller E. Use of immunoglobulin G in the treatment of nervous system diseases. Transfus Clin Biol 1995;2:57–66.PubMedCrossRefGoogle Scholar
  204. 204.
    Noseworthy JH, O’Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56(ll):14–22.Google Scholar
  205. 205.
    Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004;63(6):1081–1083.PubMedGoogle Scholar
  206. 206.
    Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343(13):898–904.PubMedCrossRefGoogle Scholar
  207. 207.
    Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J Neuro-Ophthalmol 2001(4):292–295.Google Scholar
  208. 208.
    Kinkel RP, Kollman C, O’Connor P, et al.; CHAMPIONS Study Group. IM interferon beta-la delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66(5):678–684.PubMedCrossRefGoogle Scholar
  209. 209.
    Kappos L, Polman C, Freedman MS, et al., on behalf of the BENEFIT Study Group. Betaferon® in newly emerging multiple sclerosis for initial treatment (BENEFIT): clinical results. Paper presented at 21st congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS)/ 10th annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2005 congress, September 28-October 1, 2005, Thessaloniki, Greece.Google Scholar
  210. 210.
    Beck RW, Smith CH, Gal RL, et al., Optic Neuritis Study Group. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004; 61(9):1386–1389.PubMedCrossRefGoogle Scholar
  211. 211.
    Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346(3):158–164.PubMedCrossRefGoogle Scholar
  212. 212.
    Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol 2004;61(10): 1538–1541.CrossRefGoogle Scholar
  213. 213.
    Munschauer FE III, Stuart WH. Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis. Clin Ther 1997;19(5):868–882.PubMedCrossRefGoogle Scholar
  214. 214.
    Munschauer FE III, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19(5):883–893.PubMedCrossRefGoogle Scholar
  215. 215.
    Patten SB, Metz LM. Interferon-beta 1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002;59:744–746.PubMedGoogle Scholar
  216. 216.
    Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression: a prospective investigation. J Neurol 2002;249(7): 815–820.PubMedCrossRefGoogle Scholar
  217. 217.
    Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002;59:674–678.PubMedGoogle Scholar
  218. 218.
    Wingerchuk DM, Weinshenker BG. The natural history of multiple sclerosis: implications for trial design. Curr Opin Neurol 1999;12(3): 345–349.PubMedCrossRefGoogle Scholar
  219. 219.
    Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999;53(5):1107–1114.PubMedGoogle Scholar
  220. 220.
    Yamakawa K, Kuroda H, Fujihara K, et al. Familial neuromyelitis optica (Devic’s syndrome) with late onset in Japan. Neurology 2000;55(2):318–320.PubMedGoogle Scholar
  221. 221.
    Keegan BM, Weinshenker B. Familial Devic’s disease. Can J Neurol Sci 2000;27(suppl 12): S57–58.Google Scholar
  222. 222.
    Ono T, Zambenedetti MR, Yamasaki K, et al. Molecular analysis of HLA class I (HLA-A and-B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis (Western type and Asian type). Tissue Antigens 1998;52(6):539–542.PubMedGoogle Scholar
  223. 223.
    Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPBl*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999;122(pt 9):1689–1696.PubMedCrossRefGoogle Scholar
  224. 224.
    Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002;125(pt 11):2460–2468.PubMedCrossRefGoogle Scholar
  225. 225.
    O’Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60(4):382–387.PubMedCrossRefGoogle Scholar
  226. 226.
    Bergamaschi R, Tonietti S, Franciotta D, et al. Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 2004;10(l):2–4.PubMedCrossRefGoogle Scholar
  227. 227.
    Nakashima I, Fujihara K, Fujimori J, Narikawa K, Misu T, Itoyama Y. Absence of IgGl response in the cerebrospinal fluid of relapsing neuromyelitis optica. Neurology 2004;62(l): 144–146.PubMedGoogle Scholar
  228. 228.
    Milano E, Di Sapio A, Malucchi S, et al. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. Neurol Sci 2003;24(3):130–133.PubMedCrossRefGoogle Scholar
  229. 229.
    Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473–477.PubMedCrossRefGoogle Scholar
  230. 230.
    Wingerchuk DM, Lennon VA, Pittock SJ, et al. Magnetization transfer and diffusion tensor MRI show gray matter damage in neuromyelitis optica. Neurology 2004;62(3): 476–478.Google Scholar
  231. 231.
    Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: a role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002;125(pt 7):1450–1461.Google Scholar
  232. 232.
    Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995;45(2):244–250.PubMedGoogle Scholar
  233. 233.
    Kahana E, Alter M, Feldman S. Optic neuritis in relation to multiple sclerosis. J Neurol 1976;213(2):87–95.PubMedCrossRefGoogle Scholar
  234. 234.
    Lucchinetti CF, Kiers L, O’Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997;49(5): 1413–1418.PubMedGoogle Scholar
  235. 235.
    Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987;50(6):758–765.PubMedCrossRefGoogle Scholar
  236. 236.
    Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin Proc 1997;72(9):871–878.PubMedGoogle Scholar
  237. 237.
    Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60(5): 848–853.PubMedGoogle Scholar
  238. 238.
    Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004;63(12):2363–2370.PubMedGoogle Scholar
  239. 239.
    Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2005; 7(3):173–182.PubMedCrossRefGoogle Scholar
  240. 240.
    Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51(4):1219–1220.PubMedGoogle Scholar
  241. 241.
    Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270–1272.PubMedGoogle Scholar
  242. 242.
    Bakker J, Metz L. Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004;31(2):265–267.PubMedGoogle Scholar
  243. 243.
    Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 2002; 360(9350):2018–2025.PubMedCrossRefGoogle Scholar
  244. 244.
    Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61(10):1332–1338.PubMedGoogle Scholar
  245. 245.
    Noseworthy JH. Treatment of multiple sclerosis and related disorders: what’s new in the past 2 years? Clin Neuropharmacol 2003;26(l): 28–37.PubMedCrossRefGoogle Scholar
  246. 246.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z; Interferon Beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005; 64(4):621–630.PubMedGoogle Scholar
  247. 247.
    Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58(l):143–146.PubMedGoogle Scholar
  248. 248.
    Jacobson DM. Paraneoplastic diseases of neuroophthalmologic interest. In: Miller NR, Newman NJ, editors. Walsh & Hoyt’s clinical neuroophthalmology, 5th ed. Baltimore: Williams & Wilkins; 1998.Google Scholar
  249. 249.
    Blumenthal D, Schochet S Jr, Gutman L, Ellis B, Jaynes M, Dalmau J. Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. Muscle Nerve 1998;21(10):1358–1359.PubMedCrossRefGoogle Scholar
  250. 250.
    Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis: report of case. Arch Neurol 1988;45:353–356.PubMedGoogle Scholar
  251. 251.
    De la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies. Clinical response to excision of the primary tumor. Arch Neurol 1998;55:405–408.PubMedCrossRefGoogle Scholar
  252. 252.
    Luiz J, Lee A, Keltner J, Thirkill C, Lai E. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuro-Ophthalmol 1998;18(3):178–181.CrossRefGoogle Scholar
  253. 253.
    Malik S, Furlan AJ, Sweeney PJ, Kosmorsky GS, Wong M. Optic neuropathy: a rare paraneoplastic syndrome. J Clin Neuro-Ophthalmol 1992; 12:137–141.Google Scholar
  254. 254.
    Waterston JA, Gilligan BS. Paraneoplastic optic neuritis and external ophthalmoplegia. Aust NZ J Med 1986;16:703–704.Google Scholar
  255. 255.
    Coppeto JR, Monteiro MLR, Cannarozzi DB. Optic neuropathy associated with chronic lymphomatous meningitis. J Clin Neuro-Ophthalmol 1988;8:39–45.Google Scholar
  256. 256.
    Richter RB, Morre RY. Non-invasive central nervous system disease associated with lymphoid tumors. Johns Hopkins Med J 1968;122: 271–283.PubMedGoogle Scholar
  257. 257.
    Kennedy MJ, Eustace P, O’Briain DS, Daly PA. Paraneoplastic papilloedema in neuroblastoma. Postgrad Med J 1987;63(744):873–876.PubMedGoogle Scholar
  258. 258.
    Lambrecht ER, van der Loos TL, van der Eerden AH. Retrobulbar neuritis as the first sign of the glucagonoma syndrome. Int Ophthalmol 1987;11(1):13–15.PubMedCrossRefGoogle Scholar
  259. 259.
    Hoh ST, Teh M, Chew SJ. Paraneoplastic optic neuropathy in nasopharyngeal carcinoma: report of a case. Singap Med J 1991;32: 170–173.Google Scholar
  260. 260.
    Pillay N, Gilbert JJ, Ebers GC, et al. Internuclear ophthalmoplegia and optic neuritis: paraneoplastic effects of bronchial carcinoma. Neurology 1984;34:788–791.PubMedGoogle Scholar
  261. 261.
    Yu Z, Kryzer AS, Griesmann G, Kim K, Benarroch Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146–154.PubMedCrossRefGoogle Scholar
  262. 262.
    Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and 166 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996;6:270–278.Google Scholar
  263. 263.
    Rudge P. Optic neuritis as a complication of carcinoma of the breast. Proc R Soc Med 1973; 66(11):1106–1107.PubMedGoogle Scholar
  264. 264.
    Thambisetty MR, Scherzer CR, Yu Z, Lennon VA, Newman NJ. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuro-Ophthalmol 2001;21(3):164–167.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jane W. Chan
    • 1
  1. 1.Ophthalmology and NeurologyUniversity of Kentucky College of MedicineLexingtonUSA

Personalised recommendations